MedTrace Logo

Add-on Diuretics in Acute Decompensated Heart Failure

NCT07372040 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-02-04

No results posted yet for this study

Summary

The aim of this study is to compare the efficacy and safety of empagliflozin, acetazolamide, and metolazone as add-on therapies to loop diuretics in patients with acute decompensated heart failure.

Conditions

  • Acute Decompensated Heart Failure

Interventions

DRUG

empagliflozin

Empagliflozin may augment the natriuretic and aquaretic actions of loop diuretics in patients with acute decompensated heart failure and it does not typically cause electrolyte disturbances and has been shown to improve outcomes in patients with heart failure

DRUG

Acetazolamide

Acetazolamide can augment the action of loop diuretics in patients with acute decompensated heart failure

DRUG

metolazone

Metolazone can augment the action of loop diuretics in patients with acute decompensated heart failure

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Dalia A Gomaa, MSc in clinical pharmacy · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2027-02-01
Completion
2027-02-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07372040 on ClinicalTrials.gov